Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks ribociclib combo in elderly breast cancer

NCT ID NCT06625333

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 329 older patients (65 years and up) with HR+HER2- advanced breast cancer who are taking ribociclib combined with endocrine therapy as their first or second treatment. Researchers are tracking quality of life, treatment effectiveness, and safety in real-world clinics across Russia. The goal is to see how well this therapy works in everyday practice for this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ribociclib combined with endocrine therapy (aromatase inhibitor or fulvestrant)
What this could lead to
If successful, this could help doctors understand how well this treatment works and affects quality of life in older patients, leading to better care for this age group.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the treatment. It only includes patients in Russia, so findings may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+, HER2-, ADVANCED BREAST CANCER

Contacts and locations

Locations

  • Novartis Investigative Site

    Arkhangelsk, 163045, Russia

  • Novartis Investigative Site

    Barnaul, 656045, Russia

  • Novartis Investigative Site

    Bryansk, 241028, Russia

  • Novartis Investigative Site

    Chelyabinsk, 454080, Russia

  • Novartis Investigative Site

    Irkutsk, 664035, Russia

  • Novartis Investigative Site

    Kemerovo, 650036, Russia

  • Novartis Investigative Site

    Khabarovsk, 680042, Russia

  • Novartis Investigative Site

    Khanty-Mansiysk, 628012, Russia

  • Novartis Investigative Site

    Kirov, 610021, Russia

  • Novartis Investigative Site

    Krasnoyarsk, 660022, Russia

  • Novartis Investigative Site

    Obninsk, 249036, Russia

  • Novartis Investigative Site

    Perm, 614066, Russia

  • Novartis Investigative Site

    Rostov-on-Don, 344006, Russia

  • Novartis Investigative Site

    Saint Petersburg, 194291, Russia

  • Novartis Investigative Site

    Saint Petersburg, 197758, Russia

  • Novartis Investigative Site

    Tambov, 392000, Russia

  • Novartis Investigative Site

    Tver', 170008, Russia

  • Novartis Investigative Site

    Ufa, 450054, Russia

  • Novartis Investigative Site

    Yaroslavl, 150054, Russia

  • Novartis Investigative Site

    Yekaterinburg, 620036, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.